APA (7th ed.) Citation

Schmidinger, M., Motzer, R., Powles, T., Escudier, B., Tannir, N., Mainwaring, P., . . . Choueiri, T. (2017). 2117 - Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR). European Journal of Cancer, 72, S187. https://doi.org/10.1016/S0959-8049(17)30678-0

Chicago Style (17th ed.) Citation

Schmidinger, M., et al. "2117 - Overall Survival Results from the Phase 3 Trial of Cabozantinib Vs Everolimus in Advanced Renal Cell Carcinoma (METEOR)." European Journal of Cancer 72 (2017): S187. https://doi.org/10.1016/S0959-8049(17)30678-0.

MLA (9th ed.) Citation

Schmidinger, M., et al. "2117 - Overall Survival Results from the Phase 3 Trial of Cabozantinib Vs Everolimus in Advanced Renal Cell Carcinoma (METEOR)." European Journal of Cancer, vol. 72, 2017, p. S187, https://doi.org/10.1016/S0959-8049(17)30678-0.